Navigation Links
Oncolytics Biotech Inc. Collaborators Present Positive Combination REOLYSIN(R) and Docetaxel Results at iSBTc Annual Meeting
Date:11/3/2008

urther nine patients at the top dose of REOLYSIN(R) in combination with a standard dosage of docetaxel. Patients may receive up to eight cycles of treatment in this study.

Eligible patients include those who have been diagnosed with advanced or metastatic solid tumours including bladder, lung, prostate or upper gastro-intestinal cancers that are refractory (have not responded) to standard therapy or for which no curative standard therapy exists. The primary objective of the trial is to determine the Maximum Tolerated Dose (MTD), Dose-Limiting Toxicity (DLT), recommended dose and dosing schedule and safety profile of REOLYSIN(R) when administered in combination with docetaxel. Secondary objectives include the evaluation of immune response to the drug combination, the body's response to the drug combination compared to chemotherapy alone and any evidence of anti-tumour activity.

The poster will be available today on the Oncolytics website at http://www.oncolyticsbiotech.com.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I/II and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit http://www.oncolyticsbiotech.com.

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the implication of the materials presented at this meeting with respect to REOLYSIN(R), the Company's expectations related to the results of trials investigating delivery of REOLYSIN(R), the Company's analys
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Oncolytics Biotech Inc. Collaborators to Present Combination REOLYSIN(R) and Paclitaxel/Carboplatin Results at iSBTc Annual Meeting
2. Oncolytics Biotech Inc. Collaborators to Present Combination REOLYSIN(R) and Docetaxel Results at iSBTc Annual Meeting
3. Oncolytics Biotech Inc. Collaborators Present Reovirus and Melanoma Research at EORTC-NCI-AACR Symposium
4. Oncolytics Biotech Inc. Collaborators to Present Preclinical Combination REOLYSIN(R) and Cisplatin Research at EORTC-NCI-AACR Annual Meeting
5. Media Advisory - Oncolytics Biotech Inc. to Present at BIO Investor Forum 2008
6. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
7. Oncolytics Biotech Inc. Completes Initial Scale Up of Manufacturing Process for REOLYSIN(R) to Commercial Scale
8. Media Advisory - Oncolytics Biotech Inc. to Present at Maxim Group Growth Conference
9. Oncolytics Biotech Inc. Announces Issuance of 28th U.S. Patent
10. Oncolytics Biotech Inc. Collaborators to Present REOLYSIN(R) Clinical Trial
11. Oncolytics Biotech Inc. Starts Patient Enrolment in U.S. Phase 2 Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... 27, 2015  For about a century, a ... ability to utilize and catabolize glucose at a ... is called the ,Warburg phenomenon", that is an ... oxygen presence, leading to enhanced lactate generation. Even ... choose glucose fermentation. A variety of such abnormalities ...
(Date:4/27/2015)... , April 27, 2015  Edico Genome ... and geneticists from Harvard and Stanford Universities showed ... whole genome sequence with 300x depth of coverage ... compared to 60 hours with standard software. ... a challenge, especially for individual research and clinical ...
(Date:4/27/2015)... CITY, Kan. , April 27, 2015 /PRNewswire/ ... ), a pet therapeutics company focused on the ... for companion animals, today provided commentary on clinical ... presented during a poster session at the American ... ADXS31-164 is a novel Lm ...
(Date:4/27/2015)... McKinney, Texas (PRWEB) April 27, 2015 ... products for use in applications such as animal ... fat and oil reduction in wastewater treatment plants ... be an exhibitor at the Texas Commission on ... May 5-6 in Austin, Texas. , The company ...
Breaking Biology Technology:Study Indicates Cancer Cells Alter Glucose Metabolism to Enhance Energy Production and Cell Growth 2Edico Genome, in Collaboration with Researchers from Harvard and Stanford Universities, Speeds Analysis of Whole Genome Sequence with 300x Depth of Coverage Tenfold 2Edico Genome, in Collaboration with Researchers from Harvard and Stanford Universities, Speeds Analysis of Whole Genome Sequence with 300x Depth of Coverage Tenfold 3Aratana Therapeutics Comments on ADXS31-164 (AT-014) Study Data Presented During Poster Session at the American Association for Cancer Research (AACR) Annual Meeting 2015 2DryLet to Showcase Multiple Products at Texas Commission on Environmental Quality Trade Fair and Conference May 5-6 in Austin, Texas 2
... Va., April 22 Insmed Inc. (Nasdaq:,INSM), a ... that Geoffrey Allan, Ph.D., CEO of Insmed, will ... on FOBs, on April 29,2008 at 2:15 PM ... entitled "Evaluate the Legislative, Economic and,Scientific Implications of ...
... MEDX ) announced today that it is scheduled to ... 10:30 a.m. EDT on,Wednesday, April 30, 2008. The event ... Investor Relations section of the Medarex website at, http://www.medarex.com ... available,following the event., About Medarex, Medarex is ...
... 22 /PRNewswire-FirstCall/ - Lorus Therapeutics Inc.,(,Lorus,), a ... of pharmaceutical products and technologies for the ... a development program aimed at,expanding the therapeutic ... the treatment of superficial bladder cancer., ...
Cached Biology Technology:Insmed to Present at CBI Follow-On Biologics Conference 2Insmed to Present at CBI Follow-On Biologics Conference 3Medarex to Present at the Morgan Stanley Global Healthcare Unplugged Conference 2Lorus initiates development program exploring novel route of administration for LOR-2040 2Lorus initiates development program exploring novel route of administration for LOR-2040 3Lorus initiates development program exploring novel route of administration for LOR-2040 4
(Date:4/2/2015)... , April 2, 2015 ... tests DERMALOG by far outperforms the strongest competitors, ... maintaining high accuracy, the system is capable of ... the speed proves up to be ten times ... than its runner-up performance.      (Photo: ...
(Date:4/1/2015)...   Medisafe ™, the leading global medication management ... and Android smartphones and tablets, announces ... platform to allow patients to track and correlate their ... patients will be able to visualize in real-time how ... such as glucose levels and blood pressure. ...
(Date:3/24/2015)... and Markets ( http://www.researchandmarkets.com/research/hdgz7h/global_iris ) has announced ... 2015-2019" report to their offering. The ... at a CAGR of 23.5 percent over the period ... and the growth prospects of the Global Iris Recognition ... size, the report considers the revenue generated from sales ...
Breaking Biology News(10 mins):DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2
... or grain-fed turkey this Thanksgiving, give thanks to the grasses ... and rice. Some grasses, such as corn and sugar cane, ... sun that,s more efficient in hot, arid conditions. A new ... to be. The results may one day help ...
... Mass. A new study involving bat skulls, bite force ... evolutionary biologists is helping to solve a nagging question of ... species over time while others evolve only a few. Their ... the Royal Society B: Biological Sciences . To answer ...
... Urban legend warns shoveling snow causes heart attacks, and ... excavators with a family history of premature cardiovascular disease. However, ... Two of the most important cardiology associations in ... high risk physical activity, but all the citation references indicate ...
Cached Biology News:How drought-tolerant grasses came to be 2Studying bat skulls, evolutionary biologists discover how species evolve 2